National Blood Sector Research and Development Program

A nationally coordinated effort in research and development is required to address evidence gaps in the blood sector, and to enable responses to emerging evidence and new technologies.

Under the National Blood Agreement the National Blood Authority (NBA) is charged ‘…to facilitate and fund appropriate research, policy development or other action in relation to new developments by relevant government or non-government persons or bodies.’

Research and Development Strategic Priorities

The NBA has worked with stakeholders to identify the National Blood Research and Development Strategic Priorities 2013-16. The purpose of the publication is to provide a useful resource to guide priority setting for research. It may be used by researchers to support funding requests, including from the National Health and Medical Research Council, by identifying that their research aligns with priorities communicated by governments.

National Blood Sector Research and Development Pilot

In September 2015 the NBA received approval from funding governments to offer two grant rounds under a blood sector research and development pilot.

The Pilot funded a limited number of projects which were assessed as likely to produce valuable research outcomes in identified key priority areas.  In addition, information gathered from the funded research will be used to inform consideration by governments of the viability and potential value of further blood sector specific research and development funding.

The Pilot targeted topics prioritised for research by pre-existing strategic programs of the NBA and governments in the blood sector:

  • patient blood management evidence gaps, as identified in each module of the PBM Guidelines
  • efficient and effective use of immunoglobulin products, as highlighted through the Ig Governance Program

The overarching objectives are to identify and support strategic priority areas appropriate for targeted blood sector research funding that will:

  • enhance the sustainability and affordability of the national supply of blood products, including through increased efficiency and reduced blood product usage and wastage
  • identify appropriate use and reduce inappropriate use of blood products
  • maintain or enhance clinical outcomes for patients

​by providing evidence or new knowledge to:

  • understand the biological action of blood products
  • identify optimum treatment, dosing or indications for use for blood products, and
  • compare the use of blood products with alternative strategies and treatments.

National Blood Sector Research and Development Program

Following endorsement by the Jurisdictional Blood Committee, the National Blood Sector Research and Development Program will now continue with two further funding rounds (Round 3 in 2018 and Round 4 in 2019). Funding may be available for up to three years in each round.  Projects of various types and duration will potentially be considered in the process.

Applications for grant funding will fall into one of the following categories:

  • project grants (up to 3 years)
  • seed grants (up to 1 year)
  • scholarship grants (up to 1 year)